MedTrace Logo

A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients

NCT07010939 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-09-12

No results posted yet for this study

Summary

This study, called PERSEVERE, examines how local treatment for early breast cancer affects people's health and daily lives over time.

People who join the study will have early-stage breast cancer and receive treatment such as surgery and other therapies that are used before or after surgery. The study does not include people with late-stage (metastatic) breast cancer.

Researchers want to learn about short- and long-term side effects that can happen during or after treatment. These may include tiredness, trouble sleeping, emotional distress, pain, or changes in heart or lung function. The study also looks at how these effects impact participants' quality of life.

Participants will be asked to complete surveys about how they feel. They will also have health checks, such as heart tests, lung function tests, and blood samples. Tissue samples from surgery will also be collected.

The goal is to understand better how different people respond to breast cancer treatment and find ways to support long-term recovery.

Conditions

  • Breast Neoplasms
  • Quality of Life (QOL)
  • Toxicities
  • Breast Diseases

Interventions

PROCEDURE

blood sampling

At baseline, participants will undergo peripheral blood collection using EDTA tubes. A total of 10 mL of venous blood will be collected and processed into plasma and peripheral blood mononuclear cells (PBMCs). Plasma samples will be stored at -80°C, and PBMCs will be cryopreserved in liquid nitrogen. These samples will be used for future biomarker discovery, multi-omics analysis, and studies of biological mechanisms underlying treatment-related toxicities.

Sponsors & Collaborators

  • FangYi

    lead OTHER

Principal Investigators

  • Yi Fang, MD · National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2028-05-01
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07010939 on ClinicalTrials.gov